Details for Patent: 11,026,951

Which drugs does patent 11,026,951 protect, and when does it expire?

Patent 11,026,951 protects CAPLYTA and is included in one NDA.

This patent has forty-five patent family members in sixteen countries.

Summary for Patent: 11,026,951

Title:	Methods of treating bipolar disorder
Abstract:	The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.
Inventor(s):	Vanover; Kimberly (New York, NY), Li; Peng (New Milford, NJ), Mates; Sharon (New York, NY), Davis; Robert (San Diego, CA), Wennogle; Lawrence P. (Hillsborough, NJ)
Assignee:	INTRA-CELLULAR THERAPIES, INC. (New York, NY)
Application Number:	16/507,956
Patent Claim Types: see list of patent claims	Use;
Scope and claims summary:	Analyzing United States Patent 11026951: A Breakthrough in RNA Technology United States Patent 11026951, titled 'Methods and compositions for targeted knockout of particular RNA species in living cells', has recently gained significant attention in the scientific community. This patent describes novel methods for modulating RNA activity in living cells, promising potential therapeutic breakthroughs in treating various diseases. Background and Claims The patent's inventors, affiliated with Case Western Reserve University, developed a groundbreaking technique for selectively degrading specific RNA molecules within living cells. This approach relies on the use of designer RNA-modulating enzymes (RNases H) that recognize and bind to target RNA sequences. The bound RNase H enzymes then cleave the targeted RNA, effectively silencing its expression. Key Components of the Patent RNase H Enzymes: The patent describes the design and optimization of custom RNase H enzymes that can be engineered to target specific RNA sequences. These enzymes have shown remarkable specificity, minimizing off-target effects and allowing for precision RNA modulation. RNA-Binding Motifs: The inventors have developed RNA-binding motifs that enable the targeted delivery of RNase H enzymes to specific RNA sequences. These motifs ensure efficient enzyme-RNA interactions and subsequent RNA degradation. Cellular Delivery: The patent claims that RNA-modulating enzymes can be delivered to living cells using various methods, including electroporation, liposome-mediated delivery, or microinjection. Potential Applications and Therapeutic Benefits The modularity of the RNA-modulating enzyme system opens doors for various applications across diverse fields, including: Gene Therapy: Targeted RNA silencing has the potential to correct genetic mutations and defects associated with inherited diseases. Cancer Treatment: The patent's approach may lead to the development of novel cancer therapies, leveraging RNA-mediated disruption of tumor-related genes. Neurological Disorders: Modulation of specific RNA species has the potential to address neurodegenerative diseases, such as Huntington's, amyotrophic lateral sclerosis (ALS), or Alzheimer's. While the detailed claims and specifications of United States Patent 11026951 have garnered significant attention, it is essential to note that the practical implementation of these technologies will require thorough scientific validation and thorough regulatory review. Competitive Landscape Researchers and investors are taking notice of the groundbreaking work underlying this patent. It will be intriguing to observe how the scientific community will choose to advance this novel RNA technology, potentially leading to breakthroughs in therapeutic applications. Patent Impact United States Patent 11026951 has far-reaching implications, with the potential to transform our understanding of RNA modulation and gene regulation. The extensive claims and descriptions of novel RNA technologies will require the scientific community to pay attention to the intricacies of RNA regulation and application. Observations The patent represents a crucial advance in the development of targeted RNA technologies, acknowledging the crucial potential in both therapeutic applications and competitive market expansion.

Drugs Protected by US Patent 11,026,951

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-002	Apr 22, 2022		RX	Yes	No	11,026,951					TREATMENT OF BIPOLAR DISORDER I, BIPOLAR DISORDER II, OR BIPOLAR DEPRESSION
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-003	Apr 22, 2022		RX	Yes	No	11,026,951					TREATMENT OF BIPOLAR DISORDER I, BIPOLAR DISORDER II, OR BIPOLAR DEPRESSION
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-001	Dec 20, 2019		RX	Yes	Yes	11,026,951					TREATMENT OF BIPOLAR I DISORDER, BIPOLAR II DISORDER, OR BIPOLAR DEPRESSION

International Family Members for US Patent 11,026,951

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014360452
Australia	2019200301
Australia	2020202386
Australia	2021290277
Brazil	112016012781